Giulia Zudeh

Giulia Zudeh

Auto-generated profile, based on publicly available information

Giulia Zudeh

Department of Translational and Advanced Diagnostics, Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, 34137 Trieste, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
SBStefania Braidotti
Stefania Braidotti
GZGiulia Zudeh
Giulia Zudeh
RFRaffaella Franca
Raffaella Franca
VKValentina Kiren
Valentina Kiren
ACAntonella Colombini
Antonella Colombini
MRMarco Rabusin
Marco Rabusin
High‐dose methotrexate (HD‐MTX) infusions are commonly used to consolidate remission in children with acute lymphoblastic leukemia (ALL). We investigate the potential role of candidate polymorphisms in SLCO1B1 (rs4149056 and rs2306283), ABCB1 (rs1045642), ABCC2 (rs717620), ABCC3 (rs9895420), and ABCC4 (rs7317112) drug transporters genes on HD‐MTX pharmacokinetics and patients' outcome (meant both as relapse and drug‐related toxicities) in an Italian cohort of 204 ALL pediatric patients treated according to the AIEOP‐BFM ALL 2009 protocol. TaqMan SNP genotyping assays determined patient's genotypes. Measurements of HD‐MTX plasma concentration were available for 814 HD‐MTX courses in 204 patients; MTX clearance was estimated by a two‐compartmental linear pharmacokinetic model with first‐order elimination and a Bayesian approach, via ADAPT. Independent contributions of age and ABCC4 SNP rs7317112 (A>G, intronic) on MTX clearance were detected in a multivariate analysis (p = 1.57 × 10−8 and p = 2.06 × 10−5, respectively), suggesting a delayed elimination of the drug in older patients and an accelerated one in carriers of the variant GG genotype. After multiple corrections, the association between ABCC2 SNP rs717620 (−24 C>T) and severe hematological toxicity was found (p < 0.005). Moreover, SLCO1B1 SNP rs4149056 (c.521T>C, p.V174A) affected patients' outcomes: carriers of the variant C allele presented a reduced risk of relapse compared to wild‐type TT (hazard risk: 0.27, 95% confidence interval [CI]: 0.08–0.90, p = 0.037). Taken together, these data highlighted the importance of variants in drug transporters genes on HD‐MTX disposition in the AIEOP‐BFM ALL 2009 protocol consolidation phase, and their putative role as predictive markers of outcome.

19 November 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
OMOksana Montecchini
Oksana Montecchini
SBStefania Braidotti
Stefania Braidotti
RFRaffaella Franca
Raffaella Franca
GZGiulia Zudeh
Giulia Zudeh
CBChristian Boni
Christian Boni
GSGabriele Stocco
Gabriele Stocco
The pathogenic role of the overactivated ABL1 tyrosine kinase (TK) pathway is well recognized in some forms of BCR-ABL1 like acute lymphoblastic leukemia (ALL); TK inhibitors represent a useful therapeutic choice in these patients who respond poorly to conventional chemotherapy. Here we report a novel peptide biosensor (PABL)-ELISA assay to investigate ABL1 activity in four immortalized leukemic cell lines with different genetic background. The PABL sequence comprises an ABL1 tyrosine (Y) phosphorylation site and a targeting sequence that increases the specificity for ABL1; additional peptides (Y-site-mutated (PABL-F) and fully-phosphorylated (PPHOSPHO-ABL) biosensors) were included in the assay. After incubation with whole cell lysates, average PABL phosphorylation was significantly increased (basal vs. PABL phosphorylation: 6.84 ± 1.46% vs. 32.44 ± 3.25%, p-value < 0.0001, two-way ANOVA, Bonferroni post-test, percentages relative to PPHOSPHO-ABL in each cell line). Cell lines expressing ABL1-chimeric proteins (K562, ALL-SIL) presented the higher TK activity on PABL; a lower signal was instead observed for NALM6 and REH (p < 0.001 and p < 0.05 vs. K562, respectively). Phosphorylation was ABL1-mediated, as demonstrated by the specific inhibition of imatinib (p < 0.001 for K562, NALM6, ALL-SIL and p < 0.01 for REH) in contrast to ruxolitinib (JAK2-inhibitor), and occurred on the ABL1 Y-site, as demonstrated by PABL-F whose phosphorylation was comparable to basal levels. In order to validate this novel PABL-ELISA assay on leukemic cells isolated from patient’s bone marrow aspirates, preliminary analysis on blasts derived from an adult affected by chronic myeloid leukaemia (BCR-ABL1 positive) and a child affected by ALL (BCR-ABL1 negative) were performed. Phosphorylation of PABL was specifically inhibited after the incubation of BCR-ABL1 positive cell lysates with imatinib, but not with ruxolitinib. While requiring further optimization and validation in leukemic blasts to be of clinical interest, the PABL-based ELISA assay provides a novel in vitro tool for screening both the aberrant ABL1 activity in BCR-ABL1 like ALL leukemic cells and their potential response to TK inhibitors.

30 October 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
GZGiulia Zudeh
Giulia Zudeh
SSSara Sossai
Sara Sossai
JAJacopo Angelini
Jacopo Angelini
GSGabriele Stocco
Gabriele Stocco
MLMarianna Lucafò
Marianna Lucafò
The nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome is a multiprotein complex fundamental for the secretion of pro-inflammatory cytokines during the innate immune response. NLRP3 dysregulation is implicated in the pathogenesis of several diseases, such as inflammatory bowel disease, arthritis, cancer, Alzheimer’s disease, and type 2 diabetes. The pharmacological modulation of NLRP3 by several compounds, which are fully described in this review, represents an important strategy to regulate inflammatory processes. Moreover, NLRP3 is also involved in drug-related adverse reactions, and its pharmacological modulation represents a rapid strategy to mitigate such adverse effects, as reported in this study. NLRP3 inflammasome activation is tightly regulated by post-transcriptional modifications and epigenetic factors, such as long non-coding RNAs (lncRNAs) and DNA methylation, as well as other interacting regulators. Recently, different studies have revealed the importance of NLRP3 levels in predicting drug response. In particular, the methylation of the NLRP3 promoter, which is associated with the inflammasome expression level, emerged as a new promising pharmacoepigenetic biomarker for the glucocorticoid therapy response in several inflammatory disease conditions.

5 June 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
GZGiulia Zudeh
Giulia Zudeh
MFMartina Franzin
Martina Franzin
MLMarianna Lucafò
Marianna Lucafò
MBMatteo Bramuzzo
Matteo Bramuzzo
DCDebora Curci
Debora Curci
GSGabriele Stocco
Gabriele Stocco
Azathioprine is used for inflammatory bowel disease (IBD) therapy. Patients under 6 years of age (very early onset, VEO-IBD) showed distinctive clinical characteristics, such as increased activity of thiopurine-methyltransferase (TPMT), a crucial enzyme for thiopurine metabolism. TPMT and PACSIN2 polymorphisms were associated with azathioprine efficacy. This study investigated the role of age in thiopurine active metabolites and disease activity. Also, the effects of age, TPMT and PACSIN2 polymorphisms on azathioprine metabolites and disease activity were evaluated. Erythrocytes thioguanine nucleotides (TGN) were measured by HPLC, and leukocytes incorporated deoxythioguanosine (DNA-TG) byLC-MS/MS in 12 VEO-IBD patients (median age 4.13 ± 0.98, 7 females, 6 Crohn’s disease (CD)), 11 IBD children (median age 9.36 ± 1.52, 8 females, 1 CD ), and 73 IBD adolescents (median age 14.92 ± 1.81, 33 females, 37 CD). VEO-IBD subjects required a higher azathioprine dose (p-value = 0.048) and showed a lower DNA-TG/azathioprine dose ratio (p-value = 0.049) and TGN/azathioprine dose ratio (p-value = 0.013). DNA-TG was positively correlated with TGN (p-value = 4.15 × 10–5) and disease score (p-value = 1.54 × 10–4). TPMT rs1142345 (76 wild type, 10 heterozygous) was associated with increased concentrations of DNA-TG and TGN (p-value = 0.024 and 0.00038, respectively), whereas PACSIN2 rs2413739 (37 wild types, 34 heterozygous, 16 homozygous variants) was associated with the disease score (p-value = 0.04). Together, these data confirmed that VEO-IBD patients show enhanced azathioprine metabolism, which can be accurately reflected by both TGN and DNA-TG levels, highlighting their ability to be good biomarkers of azathioprine metabolism.